Faraday Pharmaceuticals
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1616 Eastlake Ave E Ste 560, Seattle, Wa...Phone Number
(206) 492-5310Website
www.faradaypharma.comRevenue
$10.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Faraday Pharmaceuticals
Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for the prevention and treatment of cardiac and skeletal muscle loss. Their lead product, FDY-5301, which is currently in Phase 3 clinical trials, aims to mitigate reperfusion-induced damage during myocardial infarctions, addressing a critical need in cardiovascular medicine. The company focuses on enhancing patient outcomes for those experiencing heart attacks, particularly through interventions that complement existing treatments. With a foundation built on unique scientific principles, Faraday is committed to tackling unmet medical needs associated with acute and chronic diseases.Explore more
Faraday Pharmaceuticals Org Chart
ST
Chief Marketing Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Faraday Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Faraday Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Faraday Pharmaceuticals has new funding data
Earning: See what the market has to say on Faraday Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Faraday Pharmaceuticals
Faraday Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Faraday Pharmaceuticals had a recent Job posting/layoffs
Check out if Faraday Pharmaceuticals is spiking on competitors!
Check if Faraday Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Faraday Pharmaceuticals
Compare insights from companies similar to Faraday Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Faraday Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Faraday Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Faraday Pharmaceuticals.
Faraday Pharmaceuticals Tech Stack
A closer look at the technologies used by Faraday Pharmaceuticals
Faraday Pharmaceuticals News & Media
Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury
SEATTLE, April 24, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of ischemia-reperfusion injury (IRI), today announced that it will host a symposium during the Society for Cardiovascular Angiography and Interventions (SCAI) 2025 Scientific Sessions being held May 1-3, 2025, in Washington, D.C.Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury, today announced that management will present and participate in one-on-one investor meetings at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, February 11-12, 2025.Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference
SEATTLE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced that members of its management team will participate in one-on-one meetings at the Jefferies London Healthcare Conference taking place NovembeFaraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI
SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced it will host a virtual KOL webinar on Tuesday, July 30, 2024, at 11:00 AM ET. To register for the webinar, click here.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Faraday Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for the prevention and treatment of cardiac and skeletal muscle loss. Their lead product, FDY-5301, which is currently in Phase 3 clinical trials, aims to mitigate reperfusion-induced damage during myocardial infarctions, addressing a crit... Read More
